Lab
Supreme Medical Laboratories LLC
Supreme Medical Laboratories LLC was paid $1.16M by Medicaid between May 2020 and Dec 2024, across 67 billing codes. Its largest line is 87798, Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism — 31% of everything it billed.
33Billing provider infoSUPREME MEDICAL LABORATORIES LLC
FRISCO, TX 75034
FRISCO, TX 75034
33aNPI1619488418assigned 10/19/2017
33bProvider typeClinical Medical Laboratory
28Total paid$1.16M
24GClaims45,299
24DCodes billed67
24AFirst – last monthMay 2020 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Texas
Rank by total paid#65 of 436
Median peer was paid$17K
This provider vs. median67×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 2,626 | $20K | |
| 2021 | 5,297 | $81K | |
| 2022 | 8,318 | $136K | |
| 2023 | 9,108 | $31K | |
| 2024incomplete | 19,950 | $896K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 31% | 5,238 | 2,295 | $366K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 11% | 4,195 | 2,765 | $132K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 11% | 944 | 913 | $131K |
| 87481 | 7.5% | 2,534 | 2,132 | $87K | |
| 87632 | 4.9% | 649 | 609 | $57K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 3.6% | 3,013 | 2,147 | $42K |
| 87640 | 3.2% | 2,138 | 1,975 | $38K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 3.1% | 1,035 | 996 | $36K |
| 87500 | 2.1% | 1,403 | 1,320 | $24K | |
| 87653 | 1.9% | 1,045 | 978 | $22K | |
| 87563 | 1.7% | 989 | 917 | $20K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 1.5% | 179 | 175 | $18K |
55 more codes
| 87551 | 1.4% | 770 | $16K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 1.4% | 950 | $16K |
| 87556 | 1.4% | 776 | $16K | |
| 87486 | 1.3% | 829 | $15K | |
| 87581 | 1.3% | 827 | $15K | |
| 81225 | 1.2% | 568 | $14K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 1.2% | 2,148 | $13K |
| 81401 | 1.1% | 1,097 | $12K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 531 | $11K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 371 | $8K |
| 87150 | <1% | 2,054 | $7K | |
| 87511 | <1% | 304 | $6K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 287 | $5K |
| 87529 | <1% | 274 | $5K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 264 | $5K |
| 87541 | <1% | 243 | $4K | |
| 81241 | <1% | 570 | $4K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 276 | $4K |
| 81355 | <1% | 568 | $3K | |
| 81240 | <1% | 570 | $3K | |
| 81291 | <1% | 568 | $3K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 171 | $2K |
| 81226 | <1% | 574 | $2K | |
| 81105 | <1% | 413 | $1K | |
| 81227 | <1% | 574 | $928.04 | |
| 87498 | <1% | 50 | $76.65 | |
| 80061 | Lipid panel | <1% | 59 | $25.50 |
| 87641 | <1% | 17 | $15.33 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 0% | 29 | $0.00 |
| 86780 | 0% | 13 | $0.00 | |
| 81306 | 0% | 576 | $0.00 | |
| 81231 | 0% | 574 | $0.00 | |
| 87483 | 0% | 13 | $0.00 | |
| 84443 | Thyroid stimulating hormone (TSH) | 0% | 45 | $0.00 |
| 84436 | 0% | 12 | $0.00 | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 0% | 63 | $0.00 |
| 87505 | 0% | 13 | $0.00 | |
| 81283 | 0% | 39 | $0.00 | |
| 81230 | 0% | 39 | $0.00 | |
| 81350 | 0% | 39 | $0.00 | |
| 80053 | Comprehensive metabolic panel | 0% | 59 | $0.00 |
| 83036 | Hemoglobin; glycosylated (A1C) | 0% | 28 | $0.00 |
| 87181 | 0% | 13 | $0.00 | |
| 81407 | 0% | 85 | $0.00 | |
| 86684 | 0% | 13 | $0.00 | |
| 81406 | 0% | 58 | $0.00 | |
| 81404 | 0% | 58 | $0.00 | |
| 81232 | 0% | 574 | $0.00 | |
| 81479 | Unlisted molecular pathology procedure | 0% | 1,569 | $0.00 |
| 81335 | 0% | 574 | $0.00 | |
| 81408 | 0% | 34 | $0.00 | |
| 81328 | 0% | 574 | $0.00 | |
| 81405 | 0% | 59 | $0.00 | |
| 81403 | 0% | 42 | $0.00 | |
| 81249 | 0% | 39 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHARRIS, ROSS (CEO)